Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
114%(8 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
8
100%

Phase Distribution

0

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution8 total trials
Phase 3Large-scale testing
8(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 38 (100.0%)

Trials by Status

terminated113%
completed788%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_3

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

NCT00750919
completedphase_3

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)

NCT00561574
completedphase_3

Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

NCT00560833
completedphase_3

Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

NCT00535288
completedphase_3

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

NCT00561821
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00750919Phase 3

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

Terminated
NCT00561574Phase 3

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)

Completed
NCT00560833Phase 3

Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

Completed
NCT00535288Phase 3

Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Completed
NCT00561821Phase 3

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

Completed
NCT00482612Phase 3

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

Completed
NCT00631657Phase 3

A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

Completed
NCT00506389Phase 3

A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8